GynecologyGynecology2079-56962079-5831Consilium Medicum3010210.26442/2079-5696_2018.3.61-65Research ArticleThe influence of lignans on the quality of life of women of perimenopausal ageSerebrennikovaK Gklaraserebrennikova@mail.ruArutyunyanN A79687286886@yandex.ruCentral Clinical Hospital of the Russian Academy of Sciences15062018203616509042020Copyright © 2018, Consilium Medicum2018Problems associated with the state of health of women in the second half of her life are one of the priorities of modern medicine. The aim of the study was to determine the efficacy and safety of the drug in comparison with placebo in patients of perimenopausal age. Materials and methods. A randomized study was conducted in 40 patients aged 38 to 55 years without chronic somatic and gynecological diseases. The I group included 20 women who underwent therapy with the test drug (7-hydroxymatairesinol-lignan formula), in the second group - 20 women, placebo-controlled (similar dose of placebo). Conclusion. The results of the study showed that 7-hydroxymatairesinol has an effect on peripheral vasodilation, does not cause side effects (drowsiness, weakness, decreased efficiency, does not lead to fluid retention), improves general condition, causes a decrease in foliculostimulant hormone, has a positive effect on breast tissue, increases sexual activity, affects weight loss, improves carbohydrate and lipid metabolism, as well as intracellular enzymatic activity of the liver.perimenopausephytoestrogenstideslignansперименопаузафитоэстрогеныприливылигнаны[Юренева С.В., Ильина Л.М., Сметник В.П. Старение репродуктивной системы женщин: от теории к клинической практике. Часть I. Эндокринные и клинические характеристики стадий репродуктивного старения женщин. Акушерство и гинекология. 2014; 3: 21-7.][Polotsky H.N, Polotsky A.J. Metabolic implications of menopause. Semin Reprod Med 2010; 28 (5): 426-34.][Khan U.I, Wang D, Karvonen-Gutierrez C.A et al. Progression from metabolically benign to at-risk obesity in perimenopausal women: a longitudinal analysis of study of women across the nation (SWAN). J Clin Endocrinol Metab 2014; 99 (7): 2516-25.][Rees M. EMAS position statements and clinical guides. Maturitas. 2014; 77 (4): 303-4.][Wu X, Cai H, Kallianpur A et al. Age at menarche and natural menopause and number of reproductive years in association with mortality: results from a median follow-up of 11.2 years among 31.955 naturally menopausal chinese women. PLoS One 2014; 9 (8): e103673.][Yousefzadeh G, Mahdavi-Jafari F, Shokoohi M et al. Modulation of coronary artery disease risk factors by menopausal status: A population based study among Iranian women (KERCADRStudy). ARYA Atheroscler 2013; 9 (6): 332-6.][Прилепская В.Н. Климактерический синдром: инновации в менопаузальной терапии. РМЖ. 2017; 25 (2): 105-8][Heine R, Schmidt G, Knoch R et al. Postmenopausal Hormone Therapy. J Clin Endocrinol Metab 2010; 95 (1): 1-65.][Thorbjarnardottir T, Olafsdottir E.J, Valdimarsdottir U.A et al. Oral contraceptives, hormone replacement therapy and breast cancer risk: A cohort study of 16 928 women 48 years and older. Acta Oncol 2014.][Громова О.А., Торшин И.Ю., Лиманов О.А. и др. Патофизиология вегетативно-сосудистых пароксизмов (приливы) в период менопаузы у женщин и механизмы воздействия b-аланина. Новая клинико-фармакологическая концепция. Гинекология. 2010; 12 (2): 3][Andricoula V, Prelevic G. Menopausal hot flashes revisited. Climacteric 2009; 12: 3-15.][Геворкян М.А., Фаталиева К.З. Роль гормонотерапии в профилактике менопаузального метаболического синдрома. Акушерство, гинекология и репродукция. 2009; 6: 4-9.][Ледина А.В., Куликов А.Ю. Комплексное лечение и профилактика эстрогензависимых урогенитальных расстройств: клинические аспекты и фармакоэкономический анализ. Фармакоэкономика. 2009; 1: 13-8][Лихачев А.В., Галянская Е.Г., Шевлягина Л.С., Полянская И.Б. Терапия эстроген-дефицитных состояний в климактерическом периоде. Акушерство, гинекология и репродукция. 2008; 1: 4-6.][Спиридонова Н.В., Басина Е.И., Крылова О.В. Cравнительная эффективность различных схем терапии климактерических расстройств. Акушерство, гинекология и репродукция. 2012; 3: 49-55.][Фон Вольфф М., Штуте П. Гинекологическая эндокринология и репродуктивная медицина. Пер. с нем. Под общ. ред. Е.Н.Андреевой. М.: МЕДпресс-информ, 2017][Atkinson C, Franlcenfeld C, Lampe J. Gut Bacterial Metabolism of the Soy Isoflavone Daidzein: Exploring the Relevance to Human Health. Exp Biol Med 2005; 230: 155-70.][Manach C, Scalbert A, Morand C et al. Polyphenols: food sources and bioavailability. Am J Clin Nutrition 2004; 79: 727-47.][Коренная В.В. Применение фитотерапии и низкодозированной заместительной гормональной терапии в лечении климактерического синдрома. АГ-инфо. 2009; 4: 44-8][Aldercreutz H. Lignans and human health. Crit Rev Clin Lab Sci 2007; 44: 483.][Gerstenmeyer E, Reimer S, Berghofer E et al. Effect of thermal heating on some lignans in flax seeds, sesame seeds and rye. Food Chem 2013; 138 (2-3): 1847-55.][Udani J.K, Brown D.J, Tan M.O, Hardy M. Pharmacokinetics and bioavailability of plant lignan 7-hydroxymatairesinol and effects on serum enterolactone and clinical symptoms in postmenopausal women: a single-blinded, parallel, dose-comparison study. J Am Coll Nutr 2013; 32 (6): 428-35.][Smeds A.I, Eklund P.C, Willfor S.M. Chemical characterization of high-molar-mass fractions in a Norway spruce knotwood ethanol extract. Phytochemistry 2016; 130: 207-17.][Yang D, Xiao C.X, Su Z.H et al. 7(S)-hydroxymatairesinol protects against tumor necrosis factor-a-mediated inflammation response in endothelial cells by blocking the MAPK/NF-kB and activating Nrf2/HO-1. Phytomedicine 2017; 32: 15-23.]